Last reviewed · How we verify

encorafenib + binimetinib (encorafenib-binimetinib)

Pfizer Inc. · discontinued

This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mekt

Encorafenib + binimetinib is a dual BRAF/MEK inhibitor combination approved for BRAF V600E/K mutant melanoma and other solid tumors. This fixed-dose regimen targets two sequential steps in the MAPK signaling pathway, providing enhanced efficacy and improved tolerability compared to monotherapy approaches.

At a glance

Generic nameencorafenib-binimetinib
SponsorPfizer Inc.
Drug classThis arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mekt
Therapeutic areaOncology
Phasediscontinued

Mechanism of action

Cancer cells often have mutations in the BRAF gene that cause them to grow uncontrollably. Encorafenib directly blocks the abnormal BRAF protein, cutting off one growth signal. However, cancer cells can sometimes bypass this by using a backup pathway involving another protein called MEK. Binimetinib blocks this MEK protein, preventing the cancer from escaping through that alternative route. By using both drugs together, the combination attacks the cancer cell's growth machinery from two angles simultaneously. This dual approach is more effective than using just one drug alone, because it reduces the cancer's ability to develop resistance. The drugs work on the same pathway but at different checkpoints, like closing two doors instead of one to prevent escape. This combination approach is particularly effective in melanomas and other cancers that carry specific BRAF mutations. The pairing also allows doctors to use lower doses of each drug while maintaining effectiveness, which often results in fewer side effects compared to higher doses of a single agent.

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: